Drug Conference highlights delicate balance between safety and effectiveness

With Congress now considering stiffer approval hurdles for all new drugs, Lung Cancer Alliance staff Sheila Ross and Maureen Rigney participated in a high level forum on drug safety in the Capitol Building last week. HOT TOPIC: emphasizing safety in a drug for, say, headaches. that will be taken by millions of people is appropriate, but how do you balance risk and benefit of new drugs for people with end stage cancer who have run out of options? Mark McClellan, MD and PhD,former head of the FDA and Medicare, and Janet Woodcock, Deputy FDA Commissioner were among the panelists at the forum, entitled Drug Safety:Defining Safe which was hosted by Friends of Cancer Research.

Click here for LCA's Disparity Fact Sheet